biota wins a us patent for treatment of cancer, page-3

My immediate reaction to these claims by Biocrsyt that they will defend their patent because they believe they applied before Biota, is that they should also consider when Biota acquired Maxthera and Prolysis, that they also acquired their respective IP.

It is quite likely, that the patent in question may have previously been applied for by Maxthera (or Prolysis) and then, subsequent to the takeover, continuation of patent documentation popped up in Biota's name.

Anyway, time will tell.

Every way Biocryst turns, Biota trumps them - its a living nightmare for Biocryst and their investors.